Please assess the completion status of the following clinical trial:

Trial Title: KL₄Surfactant Treatment in Patients With ARDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Intubated and required mechanical ventilation support~* Met the criteria for ARDS~* Partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ≤ 200 mmHg and ≥ 60 mmHg within 60 minutes before randomization~* Mean blood pressure was ≥ 60 mmHg immediately before randomization~Exclusion Criteria:~* Had ARDS due solely to a major trauma~* Was currently participating in another clinical trial or received an experimental drug or device within the previous month~* A woman of childbearing age, unless pregnancy was excluded by a negative urine hCG test or if the subject was surgically incapable of childbearing~* Had a previous episode of ARDS that resolved and then recurred during the current hospitalization~* Had a disease that was sufficiently advanced, in the best judgment of the Principal Investigator, to markedly limit life expectancy to \< 6 months~* Was known to have AIDS or symptomatic HIV (CD4 counts \<500). Subjects with asymptomatic HIV were not excluded~* Received chemotherapy or radiation within the previous 90 days~* Received an organ transplant other than corneal transplants~* Received, or was currently receiving, immunosuppression therapy within the last 6 months~* Had severe neurological damage or the presence of a disease that was likely to significantly prevent weaning from the ventilator~* Had a best Glasgow Coma Score (GCS) of ≤ 8 or an intracranial pressure ≥ 20 cm H2O prior to the institution of sedatives or paralysis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A.1 Lucinactant (Type: EXPERIMENTAL): 3 30-mL aliquots per bronchopulmonary segment using concentrations of 5, 5, and 10 mg/mL total phopholipids. One re-treatment at 48 hours.
- A.2 Lucinactant (Type: EXPERIMENTAL): 3 30-mL aliquots per bronchopulmonary segment using concentrations of 10, 10, and 10 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
- A.3 Lucinactant (Type: EXPERIMENTAL): 2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
- A.4 Lucinactant (Type: EXPERIMENTAL): 2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
- B.1 Lucinactant (Type: EXPERIMENTAL): 2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
- B.2 Lucinactant (Type: EXPERIMENTAL): 2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
- B.3 SoC (Type: OTHER): Received standard ARDS management and ICU care (Standard of Care \[SOC\]). Included, but was not limited to, support with oxygen, conventional mechanical ventilation, sedations, and paralysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues